{"id":"NCT03073486","sponsor":"Dermira, Inc.","briefTitle":"A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris","officialTitle":"A Randomized, Double-blind, Vehicle Controlled, Efficacy and Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-06","primaryCompletion":"2017-12-21","completion":"2017-12-21","firstPosted":"2017-03-08","resultsPosted":"2019-02-05","lastUpdate":"2021-07-20"},"enrollment":744,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Olumacostat Glasaretil Gel, 5.0%","otherNames":["DRM01"]},{"type":"OTHER","name":"Olumacostat Glasaretil Gel, Vehicle","otherNames":[]}],"arms":[{"label":"Olumacostat Glasaretil Gel, 5.0%","type":"EXPERIMENTAL"},{"label":"Olumacostat Glasaretil Gel, Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The objectives of this study are to assess the safety and efficacy of Olumacostat Glasaretil Gel compared to vehicle in patients with acne vulgaris","primaryOutcome":{"measure":"Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Olumacostat Glasaretil Gel, 5.0%","deltaMin":-17,"sd":12.16},{"arm":"Olumacostat Glasaretil Gel, Vehicle","deltaMin":-15.4,"sd":11.95}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2301"}]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":46,"countries":["United States","Australia","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":491},"commonTop":["Application site pruritus","Application site pain","Application site erythema","Upper respiratory tract infection","Application site dryness"]}}